While modafinil is used as a cognitive enhancer, or "smart drug", among healthy individuals seeking improved focus and productivity,[17][18] its use outside medical supervision raises concerns regarding potential misuse or abuse.[3][7][19] Research on the cognitive enhancement effects of modafinil in non-sleep deprived individuals has yielded mixed results, with some studies suggesting modest improvements in attention and executive functions, while others show no significant benefits or a decline in cognitive functions at high doses.[20][21]
The mechanism of action is not fully defined, but is thought to act mainly as an atypical dopamine transporter inhibitor that modestly increases dopamine in cortical and striatal regions without the rapid signaling seen with classical stimulants. This effect is accompanied by activation of noradrenergic, orexin, histamine, glutamate, and GABA systems that together promote stable wakefulness and cortical activation. These combined actions likely explain modafinil's wake-promoting and cognitive effects with a lower risk of euphoria and abuse than amphetamine-like stimulants.[22][23][24][9]
Narcolepsy causes a strong urge to sleep during the day and can include symptoms like cataplexy (sudden muscle weakness), sleep paralysis (inability to move or speak while falling asleep or waking up), and hallucinations. Narcolepsy is linked to a lack of the brain chemical hypocretin (orexin), primarily produced in the hypothalamus.[28][29] Modafinil is not a cure for narcolepsy, but it can help manage the symptoms. While modafinil is primarily used to treat excessive sleepiness, it may also help reduce the frequency and severity of cataplexy attacks in some people. Modafinil is approved for management of narcolepsy with or without cataplexy. However, it is not specifically approved for the treatment of cataplexy.[30][31]
As of 2024,[update] both the French and the American Academy of Sleep Medicine strongly recommend modafinil as the first-choice treatment for narcolepsy.[36] In Europe, modafinil is considered one of the primary drugs recommended for treating narcolepsy according to the guidelines.[37]
Multiple sclerosis-related fatigue
Fatigue is a common and often debilitating symptom experienced by people with MS.[38][39]
Reviews and meta-analyses of controlled trials have found that modafinil has modest effectiveness in managing MS-related fatigue, though improvements in fatigue severity scores have not consistently reached statistical significance.[40][41] Optimal dosing and treatment schedules are not well established.[41][42] Clinical assessments have found that adverse events were common.[40][43] The American National Multiple Sclerosis Society states that modafinil can be used off-label to alleviate fatigue associated with MS.[44]
Modafinil is occasionally prescribed off-label for individuals with attention deficit hyperactivity disorder (ADHD).[45][46][47] It has not consistently shown efficacy in treating adult ADHD,[48] especially when compared to other treatments such as lisdexamfetamine.[49][50] In children, modafinil shows efficacy for ADHD symptoms in clinical trials, though it is less effective than first-line treatments such as methylphenidate and amphetamines.[51][52]
Modafinil is used off-label as an adjunctive treatment for the acute depressive phase of bipolar disorder.[54][55][56] Meta-analyses have found that add-on modafinil and armodafinil are more effective than placebo for treatment response and remission, with low rates of mood switching to mania, but the effect sizes are small and the quality of evidence is low.[57][58][59] Modafinil may also have cognitive benefits in people with bipolar disorder who are in remission.[48][60]
Military forces in several countries, including France, the United States, and the United Kingdom, have used modafinil as an alternative to amphetamines for managing fatigue during combat operations and extended missions.[61][62][63][64] The US Air Force approved modafinil for specific missions as a fatigue countermeasure.[65] Modafinil is also available to astronauts aboard the International Space Station for fatigue management.[66]
Some studies suggest significant increases in cognitive abilities, while others indicate mild to nonexistent cognitive improvements.[54][72] In some cases, it has been associated with impairments in certain cognitive functions.[20][21][73] It has been shown that a positive impact on cognitive abilities is more noticeable on sleep-deprived individuals.[74] Therefore, in people who are not sleep-deprived, the potential of modafinil as a cognitive enhancer may be limited.[75]
Sports
The regulation of modafinil as a doping agent has been controversial in the sporting world, with high-profile cases attracting press coverage since several prominent American athletes tested positive for the substance. Some athletes who used modafinil protested that the drug was not on the prohibited list at the time of their offenses.[76] However, the World Anti-Doping Agency (WADA) maintains that modafinil was related to already-banned substances. The Agency added modafinil to its list of prohibited substances on August 3, 2004, ten days before the start of the 2004 Summer Olympics.[77]
Several athletes across track and field, cycling, basketball, and rowing have tested positive for modafinil and faced sanctions, with some cases resulting in stripped medals and bans.[78][79][80]
The BALCO scandal brought to light an unsubstantiated (but widely published) account of Major League Baseball's all-time leading home-run hitter Barry Bonds' supplemental chemical regimen that included modafinil in addition to anabolic steroids and human growth hormone.[81]
Available forms
Modafinil tablets – Modalert 200 (Sun Pharma)
Modafinil is commercially available in 100mg and 200mg oral tablet forms.[7] Additionally, it is offered as the (R)-enantiomer, known as armodafinil, and as a prodrug named adrafinil.[82]
Footnotes:a = Functional activity, not binding inhibition. b = Armodafinil at D2High. Notes: No activity at a variety of other assessed targets.[83]
Modafinil's precise mechanism of action in narcolepsy and other sleep disorders remains incompletely understood.[3][24][88] Nevertheless, evidence from animal and human studies indicates that modafinil acts primarily as an atypical dopamine transporter (DAT) inhibitor or dopamine reuptake inhibitor (DRI), producing a modest increase in extracellular dopamine in cortical and striatal brain regions without inducing the rapid dopamine signaling characteristic of classical stimulants.[22]
This modest dopaminergic effect is accompanied by broader downstream activation of arousal-related neurotransmitter systems. Modafinil increases noradrenergic tone in wakefulness-promoting nuclei and indirectly engages hypothalamic orexin and histamine pathways, which together help stabilize the sleep–wake regulatory network and support sustained alertness.[23][24] Although modafinil interacts with multiple neurotransmitter systems, its exact mode of action at the molecular level remains uncertain.[24][89]
At the level of neural circuits, modafinil enhances glutamatergic excitatory transmission and reduces GABAergic inhibitory output within cortical and thalamic pathways, shifting network activity toward excitation and cortical activation while exerting minimal direct effects on classical monoamine receptors.[9] Taken together, these actions, including weak DAT inhibition combined with secondary catecholaminergic, orexinergic, glutamatergic, and GABAergic modulation, are thought to underlie modafinil's ability to promote wakefulness and cognitive function with a lower risk of euphoria and abuse than traditional amphetamine-like psychostimulants.[22][23][9]
From laboratory research, modafinil has little to no affinity for serotonin or norepinephrine transporters and does not directly interact with these systems.[19][22] However, studies have shown that elevated concentrations of norepinephrine and serotonin can occur as an indirect effect following modafinil administration due to increased extracellular dopamine activity.[22][19] Unlike traditional psychostimulant drugs,[25] such as cocaine or amphetamine, modafinil shows low potential for causing euphoria due to differences in how it interacts with dopamine transporters at a cellular level.[24][22][89]
In addition to its influence on dopaminergic pathways, modafinil may impact other neurotransmitter systems, such as orexin (hypocretin).[22] Orexin neurons are involved in promoting wakefulness and regulating arousal states. Modafinil may increase signaling within hypothalamic orexin pathways, potentially contributing to its wake-promoting effects.[19][22]
Pharmacokinetics
Cmax (peak levels) occurs approximately 2to3hours after modafinil administration.[10] Food slows the absorption of modafinil but does not affect the total area under the curve (AUC). In vitro measurements indicate that 60% of modafinil is bound to plasma proteins at clinical concentrations of the drug. This percentage changes very little when the concentration of modafinil is varied.[90]
Renal excretion of unchanged modafinil usually accounts for less than 10% of an oral dose. This means that when modafinil is taken by mouth, the only approved route of administration, less than 10% of the drug is eliminated from the body through the urine without being metabolized by the liver or other organs. The rest of the drug is either metabolized or excreted through other routes, such as feces or bile.[10]
The two major circulating metabolites of modafinil are modafinil acid (CRL-40467) and modafinil sulfone (CRL-41056). Both of these metabolites have been described as inactive, and neither appears to contribute to the wakefulness-promoting effects of modafinil.[8][91] However, modafinil sulfone does appear to possess anticonvulsant effects, a property that it shares with modafinil.[8][92]
Elimination half-life is in the range of 10 to 12 hours,[10][90] subject to differences in sex,[93] in cytochrome P450 genotypes, liver function and renal function. Modafinil is metabolized mainly in the liver,[10] and its inactive metabolites are excreted in the urine. Urinary excretion of the unchanged drug is usually less than 10% but can range from 0% to as high as 18.7%, depending on the factors mentioned.[90]
Modafinil exhibits sex-specific pharmacokinetic differences.[93] It demonstrates higher bioavailability in women compared to men. The mean Cmax is higher in women than in men, 5.2mg/L vs. 4.2mg/L (p < 0.05), following a single 200mg oral dose of modafinil.[93] This difference persists even after adjusting for body weight (0.88ml/min/kg vs. 0.72ml/min/kg).[93] The clearance of modafinil is 30% higher in men than in women, and plasma concentrations after a single dose are significantly higher in women than in men. These sex-specific pharmacokinetic differences may have implications for the efficacy and safety of modafinil.[93]
Adverse effects
Modafinil is generally well-tolerated but can have potential risks and side effects. Common adverse effects of modafinil, experienced by less than 10% of users, include headaches, nausea, and reduced appetite.[94][95][19]Anxiety, insomnia, dizziness, diarrhea, and rhinitis (nasal congestion) are also reported in 5% to 10% of users.[19] Psychiatric reactions have occurred in individuals with and without a preexisting psychiatric history.[96]Urinary retention (difficulty emptying the bladder) and paresthesia (tingling or numbness) have also been reported.[97]
Modafinil can cause a slight increase in aminotransferase enzymes, indicative of liver function, but there is no evidence of serious liver damage when levels are within reference ranges.[98]
Rare but serious adverse effects include severe skin rashes and allergy-related symptoms. Between December 1998 and January 2007, the FDA received reports of six cases of severe cutaneous adverse reactions, including erythema multiforme (target-shaped skin lesions), Stevens–Johnson syndrome, toxic epidermal necrolysis (widespread skin peeling), and DRESS syndrome (a drug reaction involving rash and organ inflammation). The FDA has issued alerts regarding these risks and also noted reports of angioedema and multi-organ hypersensitivity reactions in postmarketing surveillance.[99][100] In 2007, the FDA required Cephalon, the manufacturer of Provigil, to modify the Provigil leaflet to include warnings about these serious conditions. The long-term safety and effectiveness of modafinil have not been conclusively established.[101]
The FDA does not endorse modafinil for children's medical conditions due to an increased risk of rare but serious dermatological toxicity, manifested as Stevens–Johnson syndrome which is a type of severe skin reaction.[102][8][103] However, in Europe, modafinil may be prescribed for treating narcolepsy in children.[104]
Modafinil is contraindicated for individuals with known hypersensitivity (allergic reaction) to either modafinil or armodafinil.[7][13]
Modafinil is also contraindicated in certain cardiac conditions, including uncontrolled moderate to severe hypertension, arrhythmia, cor pulmonale,[108][109] and in cases with signs of CNS stimulant-induced mitral valve prolapse or left ventricular hypertrophy.[110][111] These contraindications arise because modafinil elicits sympathomedullary activation, producing notable increases in heart rate and blood pressure that can worsen pre-existing cardiovascular conditions.[112][113]
Clinical research has not demonstrated drug tolerance--a reduction in wakefulness-promoting and anti-fatigue effects--as a common outcome, even with therapeutic use extending up to 40 weeks.[62][115][101] However, long-term use can lead to tolerance in some individuals, necessitating higher doses to maintain efficacy.[21] People with current or past substance addictions and those with a family history of addiction are at higher risk.[21][104][116] The underlying mechanisms, which may involve dopamine and norepinephrine pathways, are not fully understood.[21][104][116] Tolerance appears more likely with off-label use for cognitive enhancement than with therapeutic use for narcolepsy, where effectiveness does not usually diminish with prolonged treatment.[21][104][116]
Addiction and dependence
Although classified as a central nervous system (CNS) stimulant, the addiction and dependence liabilities of modafinil are considered low.[7][2][27][117] The exact mechanisms of action of modafinil are not known,[24] and it is believed that pharmacological profile of modafinil is different from that of the classical stimulants such as cocaine or amphetamine.[13] Although modafinil shares biochemical mechanisms with stimulant drugs, it is less likely to have mood-elevating properties.[7] The similarities in effects with caffeine are not clearly established.[13][118] Unlike other stimulants, modafinil does not induce a strong subjective feeling of pleasure or reward or euphoria, which contributes to its lower abuse potential.[21] Albeit to a lower degree than classical stimulants, modafinil still can produce psychoactive, euphoric, and subjective effects typical for abused stimulants.[7][3]
Despite initial assessments of low abuse potential, emerging evidence suggests modafinil acts on the same neurobiological mechanisms as other addictive stimulants, warranting caution when prescribing.[75] Modafinil scores lower than amphetamine on standardized abuse-potential assessments, suggesting reduced propensity for abuse.[119]
An overdose of modafinil can lead to a range of symptoms and complications. Psychiatric symptoms may include psychosis, mania, hallucinations, and suicidal ideation, which can occur even in individuals without a history of mental illness and may persist after discontinuation of the drug.[123] Neurological complications, such as seizures, tremors, dystonia (involuntary muscle contractions), and dyskinesia (uncontrolled movements), may arise from modafinil's interaction with various neurotransmitter systems.[123]
Allergic reactions such as rash, angioedema (swelling beneath the skin), anaphylaxis (a severe whole-body allergic reaction), and Stevens–Johnson syndrome (a serious skin and mucous membrane disorder) may rarely be triggered by an immunological response to modafinil or its metabolites.[124][125] Cardiovascular complications like hypertension, tachycardia (rapid heart rate), chest pain, and arrhythmias may also occur because modafinil stimulates the sympathetic nervous system.[123]
In animal studies, the median lethal dose (LD50) of modafinil varies among species and depends on the route of administration. In mice and rats, the LD50 is approximately 1250mg/kg if administered via an injection, but the oral LD50 for rats is 3400mg/kg.[126][127] The LD50 value for humans have not been established. Human clinical trials have involved total daily doses up to 1200mg/d for 7–21days. Acute one-time total overdoses up to 4500mg have not been life-threatening but resulted in symptoms like agitation, insomnia, tremor, palpitations, and gastrointestinal disturbances.[7][128]
The management of modafinil overdose involves supportive care, monitoring of vital signs, and treatment of specific complications. In cases of recent consumption, activated charcoal, gastric lavage (stomach pumping), or hemodialysis (blood filtering) may be used.[123] There is no specific antidote for modafinil overdose.[128][129][130] The main way to deal with modafinil overdose is supportive care, which includes sedating the patient and stabilizing their blood pressure, and muscle activity in case of manifestations such as agitation or tremor.[128]
Interactions
Some of the drugs that frequently interact with modafinil include aripiprazole (an antipsychotic), amphetamine (including its enantiomers and salts; stimulants), and others.[131]
It was clinically found that modafinil affects pharmacodynamics of drugs which are metabolized by CYP3A4 and other enzymes of the cytochrome P450 family so that interactions of modafinil with these drugs were observed in real people, rather than being predicted in a lab setting.[93][132] For instance, CYP3A4 induction by modafinil can reduce plasma concentrations of opioids such as methadone, hydrocodone, oxycodone, and fentanyl, potentially causing reduced efficacy or withdrawal symptoms.[136] Modafinil also affects steroid hormones, including estradiol, progesterone, and cortisol, and can reduce the effectiveness of hormonal contraceptives for up to a month after discontinuation.[137][93][138][139] Since modafinil induces the activity of the CYP3A4 enzyme involved in cortisol clearance,[140] modafinil may reduce the bioavailability of hydrocortisone. Therefore, it may be necessary to adjust the steroid substitution dose in people receiving modafinil, which is a CYP3A4-metabolism-inducing drug.[141]
Modafinil and/or its major metabolite, modafinil acid, may be quantified in Plasma, serum, or urine to monitor dosage in those receiving the drug therapeutically, to confirm a diagnosis of poisoning in hospitalized patients, or to assist in the forensic investigation of a vehicular traffic violation.[144] Instrumental techniques involving gas or liquid chromatography are usually employed for these purposes.[72][145][146] In 2011, modafinil was not tested for by common drug screens (except for anti-doping screens) and is unlikely to cause false positives for other chemically unrelated drugs such as substituted amphetamines.[86][143][77]
Modafinil was developed in France by neurophysiology professor Michel Jouvet and Lafon Laboratories. It is part of a series of benzhydryl sulfinyl compounds, including adrafinil, initially used as a treatment for narcolepsy in France in 1986.[152] Modafinil, the primary metabolite of adrafinil,[153] has been prescribed in France since 1994 under the name Modiodal,[152] and in the United States since 1998 as Provigil.[7] Unlike modafinil, adrafinil does not have FDA approval and was withdrawn from the French market in 2011.[154]
Cephalon introduced armodafinil, the (R)-enantiomer of modafinil, in the United States in 2007. Generic versions of modafinil became available in the US in 2012 after extensive patent litigation.[158][159]
Society and culture
Modafinil's use varies by region. In the US, it is approved for adult narcolepsy, shift work sleep disorder, and obstructive sleep apnea, but not for children.[19] In the UK and the EU, since 2014, it is approved solely for narcolepsy, including in children (pediatric narcolepsy), with its use for other conditions restricted by the European Medicines Agency.[30][160] Modafinil is not approved for use by children in multiple jurisdictions.[1][161][6][7][162]
In Canada, modafinil is not a controlled substance under the Controlled Drugs and Substances Act but is classified as a Schedule F prescription drug, requiring a valid prescription.[164][165] Importing modafinil without a permit may result in seizure or prosecution.[166]
China
In mainland China, modafinil is classified as a Class I psychotropic drug, subject to strict regulation. It is available only by prescription for approved medical conditions such as narcolepsy or obstructive sleep apnea, and non-medical use is prohibited.[167][168]
Denmark
In Denmark, modafinil is a prescription drug but not listed as a controlled substance. According to the Danish Medicines Agency, modafinil is approved for use in the treatment of narcolepsy; still, importing modafinil to Denmark is considered illegal without a valid prescription.[169][170][171][172]
Finland
In Finland, modafinil is a prescription drug but not listed as a controlled substance. Finland is a member of the European Union, and it is illegal to import prescription medicine from outside the European Union unless the person has a valid prescription.[173][174][175]
Republic of Moldova
In the Republic of Moldova, modafinil is classified as a psychotropic drug and is available only by prescription.[176] Importation is illegal and subject to severe penalties.[177] In the Transnistria region, modafinil is completely prohibited under Russian-derived legislation, and possession may lead to imprisonment.[178]
Romania
In Romania, modafinil is classified as a stimulant doping agent and is prohibited in sports competitions.[179] In 2022, laws were passed making its importation or sale a felony, punishable by three to seven years in jail.[180] Simple possession for personal use may result in a fine and confiscation.[180]
Sweden
In Sweden, modafinil is classified as a scheduleIV substance, which means that it is considered to have a low potential for abuse and a low risk of dependence. Still, possession is illegal without a prescription.[181]
United Kingdom
In the United Kingdom, it is not listed in Misuse of Drugs Act, so possession is not illegal, but a prescription is required.[182]
Mexico
In Mexico, modafinil is not listed as a controlled substance, in the National Health Law, and can be purchased in pharmacies without prescription.[183]
Japan
In Japan, modafinil is a Schedule I psychotropic drug, available only by prescription and subject to strict import and export controls.[184][185]Cephalon licensed Alfresa Corporation to produce, and Mitsubishi Tanabe Pharma to sell modafinil products under the trade name Modiodal in Japan.[186] Unauthorized importation can result in criminal prosecution under the Narcotics and Psychotropics Control Law.[184]
Russia
In Russia, modafinil has been a Schedule II controlled substance since 2012. It is not approved for medical use, cannot be purchased in pharmacies, and cannot be imported even with a foreign prescription. Possession can lead to three to ten years imprisonment.[178][187] There are multiple cases of criminal proceedings initiated against Russian residents who tried to import modafinil by mail from abroad.[188][189]
South Africa
In South Africa, modafinil is ScheduleV substance, which means that it is legal to use modafinil in South Africa, but only with a valid prescription from a licensed medical practitioner.[190]
It is illegal to import modafinil to the United States without a Drug Enforcement Administration (DEA)–registered importer and a prescription.[192] Individuals may legally bring modafinil into the US from a foreign country for personal use, limited to 50 dosage units, with a prescription and proper declaration at the border.[193] Under the Pure Food and Drug Act, marketing drugs for off-label uses is prohibited.[194] Cephalon, the manufacturer of Provigil, faced legal issues for promoting off-label uses and paid significant fines in 2008.[195]
Brand names
A generic formulation of modafinil marketed under the Aspendos brand name
Modafinil is marketed under numerous brand names worldwide.[196]
Concerns have been raised about the growing use of modafinil as a "smart drug" or cognitive enhancer among healthy individuals who use it with the aim to improve concentration and memory.[197][198] In 2003, modafinil sales were skyrocketing, with some experts concerned that it had become a tempting pick-me-up for people looking for an extra edge in a productivity-obsessed society.[197] The cost of modafinil has decreased substantially since generic versions became available in the US in 2012; retail prices for generic modafinil (30 tablets of 200 mg) range from approximately $20 to $45 with discount programs, compared to over $120 per month for brand-name Provigil in 2004.[197][199][197][198][199]
As of 2024,[update] the global sales figures for modafinil are not known. Still, modafinil sold under the brand name Provigil accounted for over 40% of Cephalon's global turnover for several years, according to the information published in 2020.[200]
Patent protection and litigation
The original patent, U.S. patent 4,927,855, was granted to Laboratoire L. Lafon in 1990, covering the chemical compound of modafinil. This patent expired in 2010.[201] In 1994, Cephalon filed a patent for modafinil in the form of particles of a defined size, represented by U.S. patent 5,618,845, which expired in 2015.[202]
Following the nearing expiration of marketing rights in 2002, generic manufacturers, including Mylan and Teva, applied for FDA approval to market a generic form of modafinil, leading to legal challenges by Cephalon regarding the particle size patent.[203] The patent RE37,516 was declared invalid and unenforceable in 2011.[204]
In addition, Cephalon entered agreements with several generic drug manufacturers to delay the sale of generic modafinil in the US. These agreements were subject to legal scrutiny and antitrust investigations, culminating in a ruling by the Court of Appeals in 2016, which found that the settlements did not violate antitrust laws.[205]
Social views
The use of modafinil as a supposed cognitive enhancer may be considered as cheating, unnatural, or risky.[206] The University of Sussex explained that it is a prescription drug and the decision should be made by the doctor on whether to prescribe modafinil to a student.[207] As a matter of bioethics, the US President's Council on Bioethics argued that excellence achieved through the use of drugs like modafinil is "cheap" as it obviates the need for hard work and study, and is not fully authentic because the excellence is partly attributable to the drug, not the individual.[208] Alternately, people in Wall Street trading may consider it a tool for a competitive edge in a high-intensity environment.[209] Due to such varying views, modafinil users for narcolepsy may cope with stigma by hiding, denying, or justifying their use, or by seeking support from others who share their views or experiences.[210][211]
Research
Psychiatric conditions
Major depressive disorder
Modafinil has been studied as an adjunctive treatment for major depressive disorder.[212][213][214] While some individual trials have reported benefits,[215][216] systematic reviews and meta-analyses have found the evidence limited, the quality of evidence low, and the results inconclusive; modafinil did not significantly improve depression in network meta-analysis, though there was some evidence for reduced fatigue and sleepiness.[214][217][213]
Modafinil was investigated for ADHD because of its lower abuse potential than conventional psychostimulants,[25][218][219] but evidence for adult ADHD is mixed. A 2016 systematic review did not recommend its use,[50] and a large phase3 trial found modafinil ineffective with a high rate of side effects (86%) and discontinuation (47%), possibly due to high doses (210–510mg/d).[220] A 2008 FDA application for pediatric ADHD was denied due to concerns about rare but serious dermatological toxicity.[94]
Modafinil and armodafinil were studied as a complement to antipsychotic medications in the treatment of schizophrenia. They showed no effect on positive symptoms or cognitive performance.[226][227] A 2015 meta-analysis found that modafinil and armodafinil may slightly reduce negative symptoms in people with acute schizophrenia, though they do not appear useful for people with the condition who are stable, with high negative symptom scores.[227] Among medications demonstrated to be effective for reducing negative symptoms in combination with antipsychotics, modafinil, and armodafinil are among the smallest effect sizes.[228]
Systematic reviews have found limited evidence for modafinil as a cognitive enhancer in healthy, non-sleep-deprived individuals. A 2019 review found small enhancements in attention, executive functions, and learning, but impairments in divergent creative thinking in some studies.[232] A 2020 review reported only a modest effect on memory updating, concluding there is insufficient evidence to support the perception that modafinil is a useful cognitive enhancer.[233]
Other conditions
Modafinil has been investigated for several other conditions with inconclusive or preliminary results. Its use to relieve post-anesthesia sedation remains investigational, with studies unable to reliably verify a benefit.[120][94] Preliminary research is also examining modafinil for excessive daytime sleepiness in myotonic dystrophy, though it is not approved for this use and results are debated.[234] Modafinil has also been studied for disorders of consciousness, but observational reports have produced mixed results.[235] Caution is advised when prescribing modafinil to people with narcolepsy comorbid with postural orthostatic tachycardia syndrome.[236]
References
123"MODAFINIL SANDOZ (modafinil) tablets". TGA eBS - Product and Consumer Medicine Information Licence. Therapeutic Goods Administration (TGA); Commonwealth of Australia. Retrieved February 28, 2024.
12Robertson P, DeCory HH, Madan A, Parkinson A (June 2000). "In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil". Drug Metabolism and Disposition. 28 (6): 664–671. doi:10.1016/S0090-9556(24)15146-X. PMID10820139.
123Niemegeers P, Maudens KE, Morrens M, Patteet L, Joos L, Neels H, etal. (September 2012). "Pharmacokinetic evaluation of armodafinil for the treatment of bipolar depression". Expert Opin Drug Metab Toxicol. 8 (9): 1189–1197. doi:10.1517/17425255.2012.708338. PMID22803602.
123"Modafinil". MedlinePlus. US National Library of Medicine. February 15, 2016. Archived from the original on December 7, 2023. Retrieved February 3, 2024.
12Zamanian MY, Karimvandi MN, Nikbakhtzadeh M, Zahedi E, Bokov DO, Kujawska M, etal. (2023). "Effects of Modafinil (Provigil) on Memory and Learning in Experimental and Clinical Studies: From Molecular Mechanisms to Behaviour Molecular Mechanisms and Behavioural Effects". Current Molecular Pharmacology. 16 (4): 507–516. doi:10.2174/1874467215666220901122824. PMID36056861. S2CID252046371.
12Kakehi S, Tompkins DM (October 2021). "A Review of Pharmacologic Neurostimulant Use During Rehabilitation and Recovery After Brain Injury". Ann Pharmacother. 55 (10): 1254–1266. doi:10.1177/1060028020983607. PMID33435717. S2CID231593912.
↑Shangyan H, Kuiqing L, Yumin X, Jie C, Weixiong L (January 2018). "Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue". Multiple Sclerosis and Related Disorders. 19: 85–89. doi:10.1016/j.msard.2017.10.011. PMID29175676.
↑"Fatigue management". US National Multiple Sclerosis Society. 2025. Retrieved August 26, 2025.
↑Wilms W, Woźniak-Karczewska M, Corvini PF, Chrzanowski Ł (October 2019). "Nootropic drugs: Methylphenidate, modafinil and piracetam - Population use trends, occurrence in the environment, ecotoxicity and removal methods - A review". Chemosphere. 233: 771–785. Bibcode:2019Chmsp.233..771W. doi:10.1016/j.chemosphere.2019.06.016. PMID31200137. S2CID189861826.
↑Weiergräber M, Ehninger D, Broich K (April 2017). "Neuroenhancement and mood enhancement – Physiological and pharmacodynamical background". Medizinische Monatsschrift für Pharmazeuten. 40 (4): 154–164. PMID29952165.
↑Stuhec M, Lukić P, Locatelli I (February 2019). "Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis". The Annals of Pharmacotherapy. 53 (2): 121–133. doi:10.1177/1060028018795703. PMID30117329. S2CID52019992.
12Buoli M, Serati M, Cahn W (2016). "Alternative pharmacological strategies for adult ADHD treatment: a systematic review". Expert Review of Neurotherapeutics. 16 (2): 131–144. doi:10.1586/14737175.2016.1135735. PMID26693882. S2CID33004517.
↑Rodrigues R, Lai MC, Beswick A, Gorman DA, Anagnostou E, Szatmari P, etal. (June 2021). "Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 62 (6): 680–700. doi:10.1111/jcpp.13305. PMID32845025. S2CID221329069.
↑Bond DJ, Hadjipavlou G, Lam RW, McIntyre RS, Beaulieu S, Schaffer A, etal. (February 2012). "The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder". Annals of Clinical Psychiatry. 24 (1): 23–37. doi:10.1177/104012371202400104. PMID22303520.
↑Nunez NA, Singh B, Romo-Nava F, Joseph B, Veldic M, Cuellar-Barboza A, etal. (March 2020). "Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta-analysis of randomized controlled trials". Bipolar Disorders. 22 (2): 109–120. doi:10.1111/bdi.12859. PMID31643130.
↑Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, etal. (November 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID34509090. S2CID237485915.
↑Vaccarino SR, McInerney SJ, Kennedy SH, Bhat V (2019). "The Potential Procognitive Effects of Modafinil in Major Depressive Disorder". The Journal of Clinical Psychiatry. 80 (6). doi:10.4088/JCP.19r12767. PMID31599501. S2CID204028869.
12Billiard M, Broughton R (September 2018). "Modafinil: its discovery, the early European and North American experience in the treatment of narcolepsy and idiopathic hypersomnia, and its subsequent use in other medical conditions". Sleep Med. 49: 69–72. doi:10.1016/j.sleep.2018.05.027. PMID30174215. S2CID52143478.
↑Caldwell JA, Caldwell JL (July 2005). "Fatigue in military aviation: an overview of US military-approved pharmacological countermeasures". Aviation, Space, and Environmental Medicine. 76 (7 Suppl): C39–C51. PMID16018329.
12Keating GM, Raffin MJ (2005). "Modafinil: a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder". CNS Drugs. 19 (9): 785–803. doi:10.2165/00023210-200519090-00005. PMID16142993. S2CID43733424.
↑Battleday RM, Brem AK (November 2015). "Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review". European Neuropsychopharmacology. 25 (11): 1865–1881. doi:10.1016/j.euroneuro.2015.07.028. PMID26381811. S2CID23319688.
123Murillo-Rodríguez E, Barciela Veras A, Barbosa Rocha N, Budde H, Machado S (February 2018). "An Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil". ACS Chemical Neuroscience. 9 (2): 151–158. doi:10.1021/acschemneuro.7b00374. PMID29115823.
123Gilman A, Goodman LS, Hardman JG, Limbird LE (2001). Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill. p.1984. ISBN978-0-07-135469-1.
↑Ramachandra B (November 2016). "A Critical Review of Properties of Modafinil and Analytical, Bioanalytical Methods for its Determination". Critical Reviews in Analytical Chemistry. 46 (6): 482–489. doi:10.1080/10408347.2016.1153948. PMID26908128. S2CID34069997.
↑Chatterjie N, Stables JP, Wang H, Alexander GJ (August 2004). "Anti-narcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity". Neurochemical Research. 29 (8): 1481–1486. doi:10.1023/b:nere.0000029559.20581.1a. PMID15260124. S2CID956077.
12345678910Krystal A, Attarian H (December 2016). "Sleep Medications and Women: a Review of Issues to Consider for Optimizing the Care of Women with Sleep Disorders". Current Sleep Medicine Reports. 2 (4): 218–222. doi:10.1007/s40675-016-0060-1.
↑Bello NT (2015). "Central Nervous System Stimulants and Drugs That Suppress Appetite". In Ray SD (ed.). A worldwide yearly survey of new data in adverse drug reactions. Side Effects of Drugs Annual. Vol.37. Elsevier. pp.1–13. doi:10.1016/bs.seda.2015.08.004. ISBN978-0-444-63525-9. ISSN0378-6080.
↑Ciccone CD (2013). "Modafinil". Davis's drug guide for rehabilitation professionals. Philadelphia: F.A. Davis. ISBN978-0-8036-2589-1. Archived from the original on September 16, 2024.
↑"Modafinil". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2012. PMID31643597. NCBINBK548274 NBK548274.
↑Hou RH, Freeman C, Langley RW, Szabadi E, Bradshaw CM (September 2005). "Does modafinil activate the locus coeruleus in man? Comparison of modafinil and clonidine on arousal and autonomic functions in human volunteers". Psychopharmacology (Berl). 181 (3): 537–49. doi:10.1007/s00213-005-0013-8. PMID15983798. S2CID10265746.
↑Warot D, Corruble E, Payan C, Weil JS, Puech AJ (1993). "Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine, and placebo". European Psychiatry. 8 (4): 201–208. doi:10.1017/S0924933800002923. S2CID151797528.
12Ballon JS, Feifel D (April 2006). "A systematic review of modafinil: Potential clinical uses and mechanisms of action". The Journal of Clinical Psychiatry. 67 (4): 554–566. doi:10.4088/jcp.v67n0406. PMID16669720.
1234Reinert JP, Dunn RL (September 2019). "Management of overdoses of loperamide, gabapentin, and modafinil: a literature review". Expert Review of Clinical Pharmacology. 12 (9): 901–908. doi:10.1080/17512433.2019.1657830. PMID31422705. S2CID201063075.
↑Prince V, Philippidou M, Walsh S, Creamer D (March 2018). "Stevens-Johnson syndrome induced by modafinil". Clinical and Experimental Dermatology. 43 (2): 191–192. doi:10.1111/ced.13282. PMID29028129. S2CID204987385.
↑Milgram NW, Callahan H, Siwak C (September 1999). "Adrafinil: A Novel Vigilance Promoting Agent". CNS Drug Reviews. 5 (3): 193–212. doi:10.1111/j.1527-3458.1999.tb00100.x.
↑Nazarian S, Abdolmaleki Z, Torfeh A, Shirazi Beheshtiha SH (November 2020). "Mesenchymal stem cells with modafinil (gold nanoparticles) significantly improves neurological deficits in rats after middle cerebral artery occlusion". Experimental Brain Research. 238 (11): 2589–2601. doi:10.1007/s00221-020-05913-9. PMID32886135. S2CID221495887.
123Spiller HA, Hays HL, Aleguas A (July 2013). "Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management". CNS Drugs. 27 (7): 531–543. doi:10.1007/s40263-013-0084-8. PMID23757186.
↑Robertson P, Hellriegel ET, Arora S, Nelson M (February 2002). "Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers". Journal of Clinical Pharmacology. 42 (2): 205–214. doi:10.1177/00912700222011120. PMID11831544. S2CID29223738.
↑Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM (November 2006). "Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers". Journal of Psychopharmacology. 20 (6). SAGE Publications: 756–770. doi:10.1177/0269881106060770. PMID16401653. S2CID8033437.
↑Niwa T, Murayama N, Imagawa Y, Yamazaki H (May 2015). "Regioselective hydroxylation of steroid hormones by human cytochromes P450". Drug Metabolism Reviews. 47 (2). Informa UK Limited: 89–110. doi:10.3109/03602532.2015.1011658. PMID25678418. S2CID5791536.
↑Aquinos BM, García Arabehety J, Canteros TM, de Miguel V, Scibona P, Fainstein-Day P (2021). "[Adrenal crisis associated with modafinil use]". Medicina (in Spanish). 81 (5): 846–849. PMID34633961.
↑Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE (March 1998). "Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers". Journal of Clinical Pharmacology. 38 (3): 276–282. doi:10.1002/j.1552-4604.1998.tb04425.x. PMID9549666. S2CID26877375.
↑Baselt RC (2008). Disposition of Toxic Drugs and Chemicals in Man. Foster City, CA: Biomedical Publications. pp.1152–1153. ISBN978-0-9626523-7-0.
↑Gellad WF, Choi P, Mizah M, Good CB, Kesselheim AS (March 2014). "Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011". The American Journal of Managed Care. 20 (3): e90–e97. PMID24773330.
↑"食品药品监管总局 公安部 国家卫生计生委关于公布麻醉药品和精神药品品种目录的通知"[Notice from the Food and Drug Administration, the Ministry of Public Security, and the National Health and Family Planning Commission on publishing the catalog of narcotic drugs and psychotropic drugs] (in Chinese). China Food and Drug Administration. Archived from the original on December 5, 2018.
↑"处方管理办法(原卫生部令第53号)"[Prescription Management Measures (Former Ministry of Health Order No. 53)]. 中国政府网 (China Government Network) (in Chinese). Archived from the original on February 8, 2020. Retrieved February 8, 2019.
↑"LISTA INTERZISĂ - 2018"[Forbidden List - 2018](PDF). AGENȚIA NAȚIONALĂ ANTI-DOPING[National Anti-Doping Agency] (in Romanian). Archived from the original(PDF) on February 24, 2021.
12"LEGE 219 26/07/2021"[Law 219 26/07/2021 -]. Portal Legislativ[Romanian Legislative Portal] (in Romanian). Archived from the original on October 16, 2022. Retrieved October 16, 2022.
↑"Estupefacientes y Psicotrópicos"[Narcotic Drugs and Psychotropic Substances] (in Spanish). <! --Comisión Federal para la Protección contra Riesgos Sanitarios -->Federal Commission for Protection against Health Risks. Archived from the original on July 13, 2007.
↑"モダフィニルの向精神薬への指定"[Designation as a psychotropic drug of Modafinyl] (in Japanese). Archived from the original on May 15, 2015. Retrieved January 17, 2017.
↑"医疗用医薬品の添付文书情报-モディオダール锭100mg"[Attachment of drugs for doctors-Modio Dal 100mg]. 独立行政法人 医薬品医疗机器総合机[Pharmaceuticals and Medical Devices Agency] (in Japanese). Archived from the original on February 9, 2019.
↑Allison J (October 9, 2009). "Class Action Over Cephalon Off-Label Claims Tossed". Law360. Archived from the original on April 30, 2022. Retrieved January 12, 2022. Cephalon executives have repeatedly said that they do not condone off-label use of Provigil, but in 2002 the company was reprimanded by the FDA for distributing marketing materials that presented the drug as a remedy for tiredness, "decreased activity" and other supposed ailments. In 2008, Cephalon paid $425m and pleaded guilty to a federal criminal charge relating to its promotion of off-label uses for Provigil and two other drugs.
↑Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S (May 2017). "Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence". European Neuropsychopharmacology. 27 (5): 423–441. doi:10.1016/j.euroneuro.2017.03.003. PMID28318897. S2CID3740987.
12McIntyre RS, Lee Y, Zhou AJ, Rosenblat JD, Peters EM, Lam RW, etal. (August 2017). "The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis". Journal of Clinical Psychopharmacology. 37 (4): 412–418. doi:10.1097/JCP.0000000000000723. PMID28590365. S2CID27622964.
12Bahji A, Mesbah-Oskui L (September 2021). "Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis". Journal of Affective Disorders. 292: 416–423. doi:10.1016/j.jad.2021.05.119. PMID34144366.
↑Corp SA, Gitlin MJ, Altshuler LL (September 2014). "A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder". The Journal of Clinical Psychiatry. 75 (9): 1010–1018. doi:10.4088/JCP.13r08851. PMID25295426.
↑Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH (November 2013). "Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials". The Journal of Clinical Psychiatry. 74 (11): 1101–1107. doi:10.4088/JCP.13r08560. PMID24330897.
↑Malhi GS, Byrow Y, Bassett D, Boyce P, Hopwood M, Lyndon W, etal. (March 2016). "Stimulants for depression: On the up and up?". The Australian and New Zealand Journal of Psychiatry. 50 (3): 203–207. doi:10.1177/0004867416634208. PMID26906078. S2CID45341424.
↑Turner D (April 2006). "A review of the use of modafinil for attention-deficit hyperactivity disorder". Expert Review of Neurotherapeutics. 6 (4): 455–468. doi:10.1586/14737175.6.4.455. PMID16623645. S2CID24293088.
↑Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, etal. (January 2017). "Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis". Journal of Psychiatric Research. 84: 292–300. doi:10.1016/j.jpsychires.2016.09.034. PMID27810669.
↑Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin FR, Fidalgo TM (August 2020). "Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis". Psychopharmacology. 237 (8). Berlin: 2233–2255. doi:10.1007/s00213-020-05563-3. PMID32601988. S2CID220150476.
12Salamone JD, Correa M (January 2024). "The Neurobiology of Activational Aspects of Motivation: Exertion of Effort, Effort-Based Decision Making, and the Role of Dopamine". Annu Rev Psychol. 75: 1–32. doi:10.1146/annurev-psych-020223-012208. hdl:10234/207207. PMID37788571.
↑Kredlow MA, Keshishian A, Oppenheimer S, Otto MW (2019). "The Efficacy of Modafinil as a Cognitive Enhancer: A Systematic Review and Meta-Analysis". Journal of Clinical Psychopharmacology. 39 (5): 455–461. doi:10.1097/JCP.0000000000001085. PMID31433334. S2CID201119084.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
